You are here
Humira (Adalimumab) Maintains Remission in Children With Crohn’s Disease
The incidence of Crohn’s disease, which causes intestinal inflammation, is on the rise in children. Steroids are commonly used to treat the disorder in this population, but steroid therapy can stunt growth and delay puberty.
Researchers studied 192 patients 6 to 17 years of age in the U.S., Canada, and Europe between April 2007 and May 2010. Depending on their body weight, patients were assigned to either a high-dose or a low-dose treatment group. The high-dose group received 20 mg or 40 mg of adalimumab every other week, and the low-dose group received 10 mg or 20 mg of adalimumab every other week. More children who received the high dose of adalimumab were in remission at week 26 compared with the low-dose group, but the difference between the two groups was not statistically significant.
More than 80% of children with moderate-to-severe Crohn’s disease responded to adalimumab within 1 month (response was defined as a decrease in the Pediatric Crohn’s Disease Activity Index of 15 points or more from baseline). By 6 months, approximately 34% of the patients were in clinical remission, and after 1 year, 28.4% were in remission.
This was the largest double-blind study of an anti-TNF agent in children with Crohn’s disease.
For more information, visit the American Gastroenterological Association Web site.